Metastatic Progression and Tumour Heterogeneity |
Autore | Hollande Fred |
Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
Descrizione fisica | 1 electronic resource (312 p.) |
Soggetto topico | Medicine |
Soggetto non controllato |
clear cell renal cell carcinoma
tumor evolution tumor ecology intratumor heterogeneity multisite tumor sampling targeted therapy uterine carcinosarcoma endometrial carcinoma metaplastic carcinoma epithelial-to-mesenchymal transition clonality mutation TP53 PI3K/AKT pathway gene expression miRNA expression tumor microenvironment interstitial pH acidosis tumor heterogeneity magnetic resonance imaging hyperpolarized 13C MRI carbonic anhydrase lactic acid positron emission tomography esophageal squamous cell carcinoma precision medicine natural killer cells tumor mutation burden immunotherapy PET heterogeneity radiomics radiopharmaceuticals SUV nuclear medicine colon cancer Wnt signaling phenotypic plasticity EMT hybrid E/M collective and single-cell migration beta-catenin paradox breast cancer immune microenvironment DCIS ADH mammary gland cell fate 3D cultures organoids signaling single-cell RNAseq tumor endothelial cell metastasis angiocrine factor microsatellite instability colorectal cancer immune checkpoints deficient mismatch repair plasticity biomechanics circulating tumor cells (CTCs) extracellular vesicles metastatic niche epigenetics CTC-clusters single-cell analysis cellular heterogeneity circulating tumor cells pancreatic cancer epithelial mesenchymal plasticity target discovery review genomics intra-tumour heterogeneity subclonal diversity treatment resistance |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910557105803321 |
Hollande Fred
![]() |
||
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Urological Cancer 2021 |
Pubbl/distr/stampa | MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
Descrizione fisica | 1 electronic resource (328 pages) |
Soggetto topico |
Research
Chemistry |
Soggetto non controllato |
bladder cancer
radiotherapy radiosensitisation molecular subtypes preclinical studies bladder cancer cell lines latent cancer prostate cancer autopsy prognostic index prediction model mortality screening trial renal cell carcinoma PD-1 PD-L1 biomarkers immune checkpoint inhibitors prostatic neoplasms positron-emission tomography decision making tumor thrombus metastasectomy postoperative complications oncological outcomes radical cystectomy AHNAK2 prognosis dog comparative oncology inflammation prostatic atrophy preneoplastic lesion biomarker urine machine learning TRIPOD liquid biopsy glutaminase immunohistochemistry in situ methods prostate PSMA-RLT 177Lu-PSMA PSA mCRPC urinary bladder neoplasms Bacillus Calmette-Guérin (BCG) immunotherapy divergent differentiation variant morphology survival stereotactic body radiotherapy frail patients cancer metastasis genomic analysis microenvironment tumor ecology game theory fluorescence confocal microscopy prostate biopsy ablation margins focal therapy sphingosine 1-phosphate receptor 1 bladder carcinoma cell migration epithelial-mesenchymal transition FTY-720 OIP5 papillary renal cell carcinoma PLK1 tumorigenesis therapy image-guided magnetic resonance imaging ultrasonography biopsy abiraterone enzalutamide docetaxel novel hormonal therapies comparative effectiveness real-world treatment pattern metastatic prostate cancer epiplakin diagnosis advanced urothelial carcinoma immune checkpoint inhibitor prognostic tumour mutational board genomic signatures ctDNA inflammatory indices urothelial carcinoma frailty prognostic factor psoas muscle Hounsfield units |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910576872803321 |
MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|